Valuation: Damora Therapeutics, Inc.

Market Cap 1.89B 1.66B 1.53B 1.41B 2.68B 181B 2.73B 18.3B 7.18B 88.81B 7.11B 6.96B 308B P/E 2026 *
-16.1x
P/E 2027 * -14.8x
Enterprise Value 1.45B 1.27B 1.17B 1.08B 2.06B 139B 2.09B 14.03B 5.5B 68.05B 5.45B 5.33B 236B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
92.38%
Yield 2026 *
-
Yield 2027 * -
1 day+11.81%
1 week+2.67%
Current month+18.34%
1 month+46.85%
3 months+15.32%
6 months+50.15%
Current year+33.77%
1 week 27.18
Extreme 27.18
31.35
1 month 19.43
Extreme 19.43
31.35
Current year 16.5
Extreme 16.5001
33.99
1 year 2.45
Extreme 2.45
38.33
3 years 2.01
Extreme 2.01
92.5
5 years 2.01
Extreme 2.01
119.25
10 years 2.01
Extreme 2.01
449.75
Manager TitleAgeSince
Chief Executive Officer 55 2026-03-29
Director of Finance/CFO - 2026-04-30
Chief Tech/Sci/R&D Officer 60 2026-01-04
Director TitleAgeSince
Chairman 40 2026-03-22
Director/Board Member 42 2025-11-09
Director/Board Member 41 2025-11-09
Date Insider Type Main position Quantity % Market Cap.
07-05Sell

General Counsel

-245 0.0004%
04-30Other

Chief Financial Officer

312,535 0.5077%
03-29Free

Chief Executive Officer

2,000,000 3.3200%
Change 5-day change 1-year change 3-year change Capi.($)
+11.81%+2.67%+805.29%-52.65% 1.69B
-0.38%-3.44%+71.35%+128.83% 56.71B
+4.91%-3.30%+71.97%+92.14% 51.3B
+1.48%+5.97%+22.59%+495.47% 25.26B
-0.59%-4.68%-16.82%-12.99% 23.65B
+3.93%+7.11%+44.20%-1.96% 18.69B
+2.01%+7.22%+41.55%-24.93% 17.71B
-6.84%+4.81%+201.88%+348.11% 17.7B
-0.92%+8.90%+38.48% - 14.26B
+1.76%+2.24%+29.57%+195.70% 14.1B
Average +1.72%+3.27%+131.01%+129.75% 24.11B
Weighted average by Cap. +1.13%+2.15%+63.78%+143.70%

Financials

2026 *2027 *
Net sales - -
Net income -117M -102M -94.19M -87.15M -165M -11.14B -168M -1.13B -442M -5.47B -438M -429M -18.96B -144M -126M -116M -108M -204M -13.78B -208M -1.39B -547M -6.77B -542M -530M -23.43B
Net Debt -443M -387M -357M -331M -627M -42.27B -638M -4.28B -1.68B -20.76B -1.66B -1.63B -71.89B -326M -286M -263M -244M -462M -31.16B -470M -3.15B -1.24B -15.3B -1.23B -1.2B -53B
Logo Damora Therapeutics, Inc.
Damora Therapeutics Inc, formerly Galecto, Inc, is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company is engaged in the advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. It offers a multiple programs including asset, DMR-001, an investigational monoclonal antibody therapy targeting mutCALR. DMR-001 was designed to exclusively bind to mutCALR with exquisite selectivity, potency, and extended half-life, with potential to enable convenient, infrequent subcutaneous dosing.
Employees
7
Date Price Change Volume
26-07-09 US$30.78 +11.81% 845,659
26-07-08 US$27.53 -8.23% 678,857
26-07-07 US$30.00 +0.67% 588,472
26-07-06 US$29.80 -0.60% 725,348
26-07-02 US$29.98 +10.67% 761,150
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
30.78USD
Average target price
43.38USD
Spread / Average Target
+40.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DMRA Stock